Steve Liapis

Totus Medicines, Inc. manufactures drug products. The company is based in Cambridge, MA. The company was founded by Neil Dhawan, Jason Pontin. Neil Dhawan has been the CEO since incorporation.

Opna Bio is a clinical-stage biopharmaceutical company located in the US that focuses on discovering and developing novel oncology therapeutics. Opna's lead clinical compound, opn-2853, a bromo and extra terminal (bet) domain inhibitor, is currently in a phase 1/2 trial with ruxolitinib (jakafi®) in myelofibrosis, a chronic bone marrow disorder. The American company's team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market. The company has a broad portfolio that targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-x mental retardation protein (fmrp) and a diversified pipeline of validated oncology assets acquired from plexxikon.

Incendia Therapeutics, Inc. develops a novel class of anti-cancer therapies. The company is based in Boston, MA. The company was founded in 2003 by Laurent Audoly, Colin Glenn Begley, Olga Granaturova, Guy Travis Clifton. Laurent Audoly has been the CEO since 2003.

Garuda Therapeutics, Inc. aims to eliminate the need for donor or patient cells for blood stem cell transplants. The company is based in Natick, MA. The company's platform technology generates off-the-shelf, self-renewing blood stem cells that are HLA-compatible and transgene-free. This technology could potentially provide curative therapies for over 120 diseases. Garuda Therapeutics was founded by Dhvanit Shah, Sean Morrison, and David T. Scadden, with Dhvanit Shah serving as CEO since incorporation.

Walking Fish Therapeutics, Inc. engages in the provision of immune therapy services. It offers treatment for oncology, rare deficiency disease, regenerative medicine, and infectious disease. The company was founded by Lewis T. Williams, Mark Selby, Seenu Kothakota, and Tom Brennan and is headquartered in South San Francisco, CA.

Arbor Biotechnologies, Inc. engages in curating genetic biodiversity and discover novel protein functions from nature. The company was founded by David Arthur Svott, Winston Xia Yan, Feng Zhang and David R. Walt in 2016 and is headquartered in Cambridge, MA.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.